Colombia

Colombia

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
2.51 (2.10 - 2.89) 2019 Modelled IHME
2.56 (2.17 - 2.97) 2018 Modelled IHME
2.62 (2.22 - 3.09) 2017 Modelled IHME
2.71 (2.28 - 3.19) 2016 Modelled IHME
2.8 (2.31 - 3.32) 2015 Modelled IHME
2.85 (2.35 - 3.38) 2014 Modelled IHME
2.9 (2.41 - 3.43) 2013 Modelled IHME
2.93 (2.43 - 3.47) 2012 Modelled IHME
2.97 (2.45 - 3.50) 2011 Modelled IHME
3.02 (2.49 - 3.55) 2010 Modelled IHME
3.07 (2.56 - 3.60) 2009 Modelled IHME
3.14 (2.62 - 3.65) 2008 Modelled IHME
3.21 (2.69 - 3.74) 2007 Modelled IHME
3.28 (2.75 - 3.82) 2006 Modelled IHME
3.34 (2.77 - 3.92) 2005 Modelled IHME
3.4 (2.84 - 3.97) 2004 Modelled IHME
3.45 (2.91 - 4.03) 2003 Modelled IHME
3.51 (2.97 - 4.10) 2002 Modelled IHME
3.56 (3 - 4.19) 2001 Modelled IHME
3.6 (2.99 - 4.25) 2000 Modelled IHME
3.63 (3.01 - 4.29) 1999 Modelled IHME
3.66 (3.03 - 4.32) 1998 Modelled IHME
3.68 (3.02 - 4.37) 1997 Modelled IHME
3.71 (2.99 - 4.39) 1996 Modelled IHME
3.73 (2.95 - 4.47) 1995 Modelled IHME
3.76 (3 - 4.51) 1994 Modelled IHME
3.78 (3.02 - 4.55) 1993 Modelled IHME
3.81 (3.03 - 4.61) 1992 Modelled IHME
3.84 (3.04 - 4.72) 1991 Modelled IHME
3.86 (3.06 - 4.82) 1990 Modelled IHME
1.26 (0.91 - 1.80) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.26 (0.18 - 0.35) 2019 Modelled IHME
0.26 (0.18 - 0.35) 2018 Modelled IHME
0.27 (0.19 - 0.36) 2017 Modelled IHME
0.29 (0.20 - 0.40) 2016 Modelled IHME
0.31 (0.21 - 0.42) 2015 Modelled IHME
0.31 (0.22 - 0.42) 2014 Modelled IHME
0.32 (0.23 - 0.42) 2013 Modelled IHME
0.32 (0.23 - 0.41) 2012 Modelled IHME
0.32 (0.23 - 0.42) 2011 Modelled IHME
0.33 (0.23 - 0.42) 2010 Modelled IHME
0.34 (0.24 - 0.43) 2009 Modelled IHME
0.35 (0.25 - 0.45) 2008 Modelled IHME
0.37 (0.26 - 0.48) 2007 Modelled IHME
0.4 (0.28 - 0.52) 2006 Modelled IHME
0.42 (0.30 - 0.58) 2005 Modelled IHME
0.49 (0.34 - 0.66) 2004 Modelled IHME
0.59 (0.42 - 0.79) 2003 Modelled IHME
0.7 (0.51 - 0.92) 2002 Modelled IHME
0.79 (0.58 - 1.04) 2001 Modelled IHME
0.83 (0.60 - 1.09) 2000 Modelled IHME
0.82 (0.60 - 1.08) 1999 Modelled IHME
0.82 (0.59 - 1.07) 1998 Modelled IHME
0.81 (0.57 - 1.06) 1997 Modelled IHME
0.8 (0.57 - 1.05) 1996 Modelled IHME
0.79 (0.56 - 1.06) 1995 Modelled IHME
0.87 (0.60 - 1.15) 1994 Modelled IHME
1.06 (0.74 - 1.42) 1993 Modelled IHME
1.34 (0.93 - 1.81) 1992 Modelled IHME
1.69 (1.17 - 2.31) 1991 Modelled IHME
2.07 (1.43 - 2.83) 1990 Modelled IHME
0.21 (0.13 - 0.33) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
17 (12 - 23) 2019 Modelled IHME
17 (12 - 24) 2018 Modelled IHME
17 (12 - 24) 2017 Modelled IHME
17 (12 - 24) 2016 Modelled IHME
17 (12 - 24) 2015 Modelled IHME
17 (12 - 24) 2014 Modelled IHME
17 (12 - 24) 2013 Modelled IHME
18 (13 - 24) 2012 Modelled IHME
18 (13 - 25) 2011 Modelled IHME
18 (13 - 25) 2010 Modelled IHME
18 (13 - 25) 2009 Modelled IHME
18 (13 - 25) 2008 Modelled IHME
18 (13 - 25) 2007 Modelled IHME
19 (13 - 25) 2006 Modelled IHME
19 (14 - 26) 2005 Modelled IHME
19 (14 - 26) 2004 Modelled IHME
19 (14 - 26) 2003 Modelled IHME
20 (14 - 27) 2002 Modelled IHME
20 (14 - 27) 2001 Modelled IHME
20 (15 - 27) 2000 Modelled IHME
20 (15 - 27) 1999 Modelled IHME
21 (15 - 28) 1998 Modelled IHME
21 (15 - 28) 1997 Modelled IHME
21 (15 - 28) 1996 Modelled IHME
21 (16 - 28) 1995 Modelled IHME
21 (16 - 28) 1994 Modelled IHME
21 (16 - 28) 1993 Modelled IHME
21 (16 - 29) 1992 Modelled IHME
21 (16 - 29) 1991 Modelled IHME
21 (16 - 28) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
77 2018 Survey/reported WHO/UNICEF
81 2017 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
92 2018 Survey/reported WHO/UNICEF
92 2017 Survey/reported WHO/UNICEF
91 2016 Survey/reported WHO/UNICEF
91 2015 Survey/reported WHO/UNICEF
90 2014 Survey/reported WHO/UNICEF
91 2013 Survey/reported WHO/UNICEF
92 2012 Survey/reported WHO/UNICEF
85 2011 Survey/reported WHO/UNICEF
88 2010 Survey/reported WHO/UNICEF
92 2009 Survey/reported WHO/UNICEF
92 2008 Survey/reported WHO/UNICEF
93 2007 Survey/reported WHO/UNICEF
93 2006 Survey/reported WHO/UNICEF
93 2005 Survey/reported WHO/UNICEF
89 2004 Survey/reported WHO/UNICEF
92 2003 Survey/reported WHO/UNICEF
78 2002 Survey/reported WHO/UNICEF
80 2001 Survey/reported WHO/UNICEF
78 2000 Survey/reported WHO/UNICEF
77 1999 Survey/reported WHO/UNICEF
75 1998 Survey/reported WHO/UNICEF
85 1997 Survey/reported WHO/UNICEF
95 1996 Survey/reported WHO/UNICEF
71 1995 Survey/reported WHO/UNICEF
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
Pregnant women
HBV testing policy
Risk-based
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Eligible for HBV generic medicines
No
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based
Eligible for HCV generic medicines
Yes
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.75 (1.40 - 2.16) 2019 Modelled IHME
1.74 (1.40 - 2.14) 2018 Modelled IHME
1.73 (1.40 - 2.13) 2017 Modelled IHME
1.72 (1.39 - 2.10) 2016 Modelled IHME
1.71 (1.37 - 2.09) 2015 Modelled IHME
1.74 (1.41 - 2.10) 2014 Modelled IHME
1.8 (1.49 - 2.15) 2013 Modelled IHME
1.88 (1.57 - 2.21) 2012 Modelled IHME
1.96 (1.64 - 2.29) 2011 Modelled IHME
1.99 (1.67 - 2.34) 2010 Modelled IHME
2 (1.68 - 2.36) 2009 Modelled IHME
2.01 (1.67 - 2.38) 2008 Modelled IHME
2.02 (1.68 - 2.38) 2007 Modelled IHME
2.03 (1.68 - 2.39) 2006 Modelled IHME
2.03 (1.68 - 2.41) 2005 Modelled IHME
2 (1.65 - 2.36) 2004 Modelled IHME
1.92 (1.58 - 2.27) 2003 Modelled IHME
1.83 (1.50 - 2.20) 2002 Modelled IHME
1.76 (1.42 - 2.13) 2001 Modelled IHME
1.72 (1.38 - 2.12) 2000 Modelled IHME
1.73 (1.39 - 2.11) 1999 Modelled IHME
1.75 (1.41 - 2.14) 1998 Modelled IHME
1.77 (1.42 - 2.18) 1997 Modelled IHME
1.79 (1.44 - 2.19) 1996 Modelled IHME
1.8 (1.45 - 2.23) 1995 Modelled IHME
1.81 (1.45 - 2.23) 1994 Modelled IHME
1.81 (1.45 - 2.23) 1993 Modelled IHME
1.81 (1.45 - 2.24) 1992 Modelled IHME
1.81 (1.45 - 2.24) 1991 Modelled IHME
1.81 (1.45 - 2.26) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

People who inject drugs (PWID)
Download
Value (%) Year Type Source
28.8 (26.20 - 31.60) 2014 Survey/reported Berbesi S et al, 2016

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
39 (30 - 48) 2019 Modelled IHME
38 (29 - 47) 2018 Modelled IHME
38 (29 - 47) 2017 Modelled IHME
38 (29 - 47) 2016 Modelled IHME
39 (29 - 48) 2015 Modelled IHME
39 (29 - 48) 2014 Modelled IHME
38 (29 - 47) 2013 Modelled IHME
38 (29 - 47) 2012 Modelled IHME
38 (29 - 47) 2011 Modelled IHME
38 (29 - 47) 2010 Modelled IHME
38 (29 - 47) 2009 Modelled IHME
38 (29 - 47) 2008 Modelled IHME
38 (29 - 47) 2007 Modelled IHME
38 (29 - 47) 2006 Modelled IHME
38 (29 - 47) 2005 Modelled IHME
38 (29 - 46) 2004 Modelled IHME
37 (29 - 46) 2003 Modelled IHME
37 (28 - 46) 2002 Modelled IHME
37 (29 - 46) 2001 Modelled IHME
37 (28 - 45) 2000 Modelled IHME
37 (28 - 45) 1999 Modelled IHME
37 (28 - 45) 1998 Modelled IHME
37 (28 - 45) 1997 Modelled IHME
36 (28 - 45) 1996 Modelled IHME
36 (28 - 45) 1995 Modelled IHME
36 (28 - 44) 1994 Modelled IHME
36 (28 - 45) 1993 Modelled IHME
36 (28 - 45) 1992 Modelled IHME
36 (28 - 44) 1991 Modelled IHME
36 (28 - 45) 1990 Modelled IHME
Showing out of
Show more
Technical notes
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
Pregnant women
HBV testing policy
Risk-based
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Eligible for HBV generic medicines
No
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based
Eligible for HCV generic medicines
Yes
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No

Overview

HBV elimination goal
Year of goal
2030
HCV elimination goal
Year of goal
2030

Prevalence (national)

Modelled

HBV (HBsAg+)
2.51 (%)
2019
(2.1 - 2.89(%))
IHME
HCV (RNA/cAg+)
1.75 (%)
2019
(1.4 - 2.16(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
355
2019
(245 - 500)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
1,451
2019
(1,023 - 1,960)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.26 (%)
2019, latest modelled
(0.18 - 0.35(%))
IHME

Prevalence PWID

HCV
28.80 (%)
2014, survey/surveillance
(26.20 - 31.60(%))
Berbesi S et al, 2016

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
77 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
No
Eligible for HCV generic medicines
Yes